Literature DB >> 24034515

How can we monitor glycaemic variability in the clinical setting?

S Inchiostro1, R Candido, F Cavalot.   

Abstract

No universal consensus exists on how to express glycaemic variability. Among other parameters, standard deviation of blood glucose values, mean amplitude of glycaemic excursions (MAGE), the Low Blood Glucose Index (LBGI) and the High Blood Glucose Index (HBGI), which were subsequently combined into the Average Daily Risk Range (ADRR), mean of daily differences (MODD) and glycaemic variability index (GVI) are highlighted. The continuous glucose monitoring in research and clinical settings has been a great help for a comprehensive approach to circadian blood glucose evaluation and identification of individual patterns, mainly in type 1 diabetes, but recently also in type 2 diabetes. In everyday clinical practice the judicious use of self-monitoring of blood glucose in an educational setting involving the patient and the care team is an unreplaceable tool to effectively and safely guide behavioural and drug therapy.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  continuous glucose monitoring; glycaemic variability; self-monitoring of blood glucose; type 1 diabetes; type 2 diabetes

Mesh:

Substances:

Year:  2013        PMID: 24034515     DOI: 10.1111/dom.12142

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  9 in total

1.  Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study.

Authors:  Guoli Du; Wanrun Xie; Yinxia Su; Yao Ma; Xiaoming Gao; Sheng Jiang; Huazheng Liang
Journal:  PeerJ       Date:  2020-10-02       Impact factor: 2.984

2.  Q-Score: development of a new metric for continuous glucose monitoring that enables stratification of antihyperglycaemic therapies.

Authors:  Petra Augstein; Peter Heinke; Lutz Vogt; Roberto Vogt; Christine Rackow; Klaus-Dieter Kohnert; Eckhard Salzsieder
Journal:  BMC Endocr Disord       Date:  2015-05-01       Impact factor: 2.763

3.  Not Only Glycaemic But Also Other Metabolic Factors Affect T Regulatory Cell Counts and Proinflammatory Cytokine Levels in Women with Type 1 Diabetes.

Authors:  Katerina Stechova; Jana Sklenarova-Labikova; Tereza Kratzerova; Pavlina Pithova; Dominik Filipp
Journal:  J Diabetes Res       Date:  2017-05-03       Impact factor: 4.011

4.  Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia.

Authors:  Ronnie Aronson; Guillermo Umpierrez; William Stager; Boris Kovatchev
Journal:  Diabetes Obes Metab       Date:  2018-12-10       Impact factor: 6.577

Review 5.  Glycemic Variability: How Do We Measure It and Why Is It Important?

Authors:  Sunghwan Suh; Jae Hyeon Kim
Journal:  Diabetes Metab J       Date:  2015-08       Impact factor: 5.376

6.  Complications of Diabetes.

Authors:  Konstantinos Papatheodorou; Maciej Banach; Michael Edmonds; Nikolaos Papanas; Dimitrios Papazoglou
Journal:  J Diabetes Res       Date:  2015-07-12       Impact factor: 4.011

7.  The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.

Authors:  Athena Philis-Tsimikas; Wendy Lane; Ulrik Pedersen-Bjergaard; Carol Wysham; Lars Bardtrum; Signe Harring; Simon Heller
Journal:  Diabetes Obes Metab       Date:  2020-01-24       Impact factor: 6.577

8.  Effectiveness of Insulin Degludec in Thai Patients with Diabetes Mellitus: Real-World Evidence From a Specialized Diabetes Center.

Authors:  Yotsapon Thewjitcharoen; Nalin Yenseung; Areeya Malidaeng; Siriwan Butadej; Phawinpon Chotwanvirat; Sirinate Krittiyawong; Chattip Thammawiwat; Thep Himathongkam
Journal:  Exp Clin Endocrinol Diabetes       Date:  2019-10-09       Impact factor: 2.949

9.  The Multi-Domain Intervention Trial in Older Adults With Diabetes Mellitus for Prevention of Dementia in Japan: Study Protocol for a Multi-Center, Randomized, 18-Month Controlled Trial.

Authors:  Taiki Sugimoto; Atsushi Araki; Hiroki Fujita; Keiko Honda; Nobuya Inagaki; Takeshi Ishida; Junichi Kato; Minoru Kishi; Kazuki Kobayashi; Kunichi Kouyama; Hisashi Noma; Mitsuru Ohishi; Noriko Satoh-Asahara; Hiroyuki Shimada; Kazuhiro Sugimoto; Susumu Suzuki; Yasushi Takeya; Yoshiaki Tamura; Haruhiko Tokuda; Hiroyuki Umegaki; Hirotaka Watada; Yuichiro Yamada; Takashi Sakurai
Journal:  Front Aging Neurosci       Date:  2021-07-12       Impact factor: 5.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.